Mechanism of erythropoietin-induced hypertension.
Chronic administration of erythropoietin (EPO) is associated with an increase in arterial blood pressure in patients and animals with chronic renal failure (CRF). Several mechanisms have been considered in the pathogenesis of EPO-induced hypertension. These include the possible role of the rise of hematocrit and erythrocyte mass, changes in production or sensitivity to endogenous vasopressors, alterations in vascular smooth-muscle ionic milieu, dysregulation of production or responsiveness to endogenous vasodilatory factors, a direct vasopressor action of EPO, and finally arterial remodeling through stimulation of vascular cell growth.
Vaziri
N D
ND
Department of Medicine, University of California, Irvine, CA, USA. tabotten@uci.edu
D000740:Anemia / Q000150:complications / Q000188:drug therapy; D000818:Animals; D002395:Catecholamines / Q000097:blood; D016232:Endothelins / Q000097:blood; D004911:Erythrocyte Volume; D004921:Erythropoietin / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D006400:Hematocrit; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000139:chemically induced / Q000209:etiology*; D007676:Kidney Failure, Chronic / Q000150:complications; D012084:Renin-Angiotensin System / Q000502:physiology; D013997:Time Factors; D014662:Vasoconstrictor Agents / Q000009:adverse effects* / Q000627:therapeutic use
D002395:Catecholamines; D016232:Endothelins; D014662:Vasoconstrictor Agents; D004921:Erythropoietin